ArticleOncotarget2016

Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.

Ming-Mo Hou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.